RNA transfection

CGTN: New Approaches : How China pushes COVID-19 vaccine R&D and inoculation

Retrieved on: 
Tuesday, December 20, 2022
Tao, COVID-19 vaccine, Vaccination, World Health Organization, Respiratory disease, Injection, WHO, Immune system, RNA transfection, COVID-19, NHC, Coronavirus, National Government, Epidemiology, Fortis Healthcare, Infection, Vaccine, National Health Commission, Ageing, Animal, Pharmaceutical industry, Aquaculture, Sinovac Biotech

It made substantial progress of vaccine development in five different technologies including inactivated vaccine, viral vector vaccine, recombinant protein vaccine, live attenuated influenza vaccine and nucleic acid vaccine.

Key Points: 
  • It made substantial progress of vaccine development in five different technologies including inactivated vaccine, viral vector vaccine, recombinant protein vaccine, live attenuated influenza vaccine and nucleic acid vaccine.
  • Three years into pandemic, China has approved 13 COVID-19 vaccines, including five inactivated vaccines, five recombinant protein vaccines, two viral vector vaccines and one live attenuated influenza vaccine.
  • China also has the most inoculation plans for its domestically developed COVID-19 vaccines that are based on inactivated virus, viral vector and recombinant protein.
  • China, with a population of 1.4 billion, has had administered nearly 3.46 billion doses of COVID-19 vaccines nationwide and provided over 2 billion doses worldwide.

Outstanding results for Eurocine Vaccines´ mRNA based HSV-2 candidate

Retrieved on: 
Tuesday, December 20, 2022
Spleen, Vaccination, Herpes simplex virus, Vaccine, Ganglion, Infection, CD8, RNA transfection, HSV-2, Mouse, News, Immunization, CD4, Relevant

The initial results demonstrate that immune responses in mice immunized with the mRNA candidate are not only non-inferior to those elicited by their protein counterpart.

Key Points: 
  • The initial results demonstrate that immune responses in mice immunized with the mRNA candidate are not only non-inferior to those elicited by their protein counterpart.
  • In fact, the mRNA vaccine generates superior T cell responses.
  • Results from the study, comparing the two technology platforms at multiple doses, demonstrate that the mRNA and the protein vaccines were well tolerated and generated T cell and antibody responses.
  • "I am overwhelmed by these results" says Dr. Karl Ljungberg, Director of Preclinical Development at Eurocine Vaccines.

Outstanding results for Eurocine Vaccines´ mRNA based HSV-2 candidate

Retrieved on: 
Tuesday, December 20, 2022
Spleen, Vaccination, Herpes simplex virus, Vaccine, Ganglion, Infection, CD8, RNA transfection, HSV-2, Mouse, News, Immunization, CD4, Relevant

The initial results demonstrate that immune responses in mice immunized with the mRNA candidate are not only non-inferior to those elicited by their protein counterpart.

Key Points: 
  • The initial results demonstrate that immune responses in mice immunized with the mRNA candidate are not only non-inferior to those elicited by their protein counterpart.
  • In fact, the mRNA vaccine generates superior T cell responses.
  • Results from the study, comparing the two technology platforms at multiple doses, demonstrate that the mRNA and the protein vaccines were well tolerated and generated T cell and antibody responses.
  • "I am overwhelmed by these results" says Dr. Karl Ljungberg, Director of Preclinical Development at Eurocine Vaccines.

Sirnaomics Marks 15th Anniversary with Opening of New US Headquarters and Laboratories in Germantown, Maryland

Retrieved on: 
Monday, December 19, 2022
RNA interference, Maryland Department of Commerce, RNA, RNA transfection, Laboratory, Commerce, Multimedia, Infection, Therapy, Cancer, HK, IPO, Degenerative disease, Pharmaceutical industry

The new 50,375 square foot facility in the Seneca Meadows Corporate Center offers Sirnaomics USA ample space for current staff as well as for future expansion.

Key Points: 
  • The new 50,375 square foot facility in the Seneca Meadows Corporate Center offers Sirnaomics USA ample space for current staff as well as for future expansion.
  • Carla Meritt of Maryland Department of Commerce, Montgomery County Executive Marc Elrich and other representatives delivered congratulatory remarks and certificates to Sirnaomics.
  • Sirnaomics is the first biopharmaceutical company to achieve positive Phase IIa clinical outcomes in oncology clinical-stage RNA therapeutics.
  • With nearly 200 staffers world-wide, including 80 in the U.S., Sirnaomics has established a significant presence, developing its own proprietary and novel delivery platforms.

Regen BioPharma, Inc. issues Message to the Shareholders from the Chairman And Chief Executive Officer

Retrieved on: 
Monday, December 19, 2022
OTC, Patient, Cros, Tumor microenvironment, NR2F6, Cell, SAN, CAR, PINK, University, RNA transfection, Regulation, Lymphoma, News, Degenerative disease, Coronavirus Scientific Advisory Board (Turkey), Science, New Year, Leukemia, Sale, Immunosuppression, Cancer, Security (finance), Vaccine, Pharmaceutical industry

We accomplished this by filing 4 new patents applications in the areas of mRNA vaccines and CAR T-cell therapies.

Key Points: 
  • We accomplished this by filing 4 new patents applications in the areas of mRNA vaccines and CAR T-cell therapies.
  • In addition, we had 2 patents issued by the US patent office which protect our composition of matter around inhibiting and activating NR2F6 using small molecules.
  • While the Company has many exciting pipeline products, we need to focus our limited resources towards what we believe will provide patients and our shareholders the maximum benefit.
  • Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

Synthetic Biology Market worth $30.7 billion by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, December 19, 2022
Merck, Novozymes, RNA, GenScript Biotech, RNA transfection, Synthetic biology, Oligonucleotide, Enzyme, Twist Bioscience, Synthetic Genomics (company), DNA, Agilent Technologies, Vaccine, Investment, Research, Acquisition, Merck Group, Food, Agriculture, Conservation, and Trade Act of 1990, Fine chemical, Agriculture

The oligonucleotides and synthetic DNA segment accounted for the largest share of the tool segment in the synthetic biology market.

Key Points: 
  • The oligonucleotides and synthetic DNA segment accounted for the largest share of the tool segment in the synthetic biology market.
  • On the basis of tool, the synthetic biology market is broadly segmented into oligonucleotides & synthetic DNA, enzymes, cloning technology kits, synthetic cells, chassis organisms, and xeno-nucleic acids.
  • In 2020, oligonucleotides & synthetic DNA accounted for the largest share of the synthetic biology market for tools.
  • The medical applications segment accounted for the largest share of the application segment in the synthetic biology market.

Guo Guangchang looks back on Fosun's 30 years and reveals the future development direction of Fosun

Retrieved on: 
Monday, December 19, 2022
Acquisition, Speech, Fosun Pharma, BioNTech, Vaccination, Health, Chinese New Year, Happiness, Omicron, Club Med, Pressure, LANV, Face, RNA transfection, Patient, Epidemic, Growth, Lanvin, COVID-19, Wolford, Nightclub, Retail, Pharmaceutical industry, Vaccine, Azvudine, Fosun International

Market analysts believe that Fosun is actively making strategic focus in the face of the constant changes in the macro environment.

Key Points: 
  • Market analysts believe that Fosun is actively making strategic focus in the face of the constant changes in the macro environment.
  • On 15 December, Fosun held the Fosun's 30th Anniversary ONE FOSUN Family Members' Carnival.
  • In Guo Guangchang's speech on 15 December, he shared the moment of the successful acquisition of Club Med in 2015.
  • Guo Guangchang said, "BioNTech, a Germany biotechnology company, chose to cooperate with Fosun to develop the COVID-19 mRNA vaccine because they recognize Fosun Pharma's research and development capabilities and globalization strategy.

hC Bioscience Appoints Martin Maier, Ph.D. To its Scientific Advisory Board; Brings Expertise in Therapeutic Nucleic Acid Development and Delivery

Retrieved on: 
Wednesday, December 7, 2022
Disease, SAB, United States Air Force Scientific Advisory Board, Mutation, PTC Therapeutics, RNA transfection, Therapy, Patient, Medical device, Telescopic sight, Vaccine

Cambridge, Massachusetts--(Newsfile Corp. - December 7, 2022) - hC Bioscience, Inc., a pioneer in the development of tRNA-based therapeutics, appointed Martin Maier, Ph.D., to its Scientific Advisory Board.

Key Points: 
  • Cambridge, Massachusetts--(Newsfile Corp. - December 7, 2022) - hC Bioscience, Inc., a pioneer in the development of tRNA-based therapeutics, appointed Martin Maier, Ph.D., to its Scientific Advisory Board.
  • Dr. Maier's background will bring, among other contributions, an expertise in nucleic acid chemistry and delivery, and the development of nucleic acid therapeutics.
  • hC Bioscience names Martin Maier, Ph.D., to its Scientific Advisory Board.
  • Dr. Maier's background will bring an expertise in nucleic acid chemistry and delivery, and the development of nucleic acid therapeutics.

EQS-News: Defence Therapeutics Inc.: DEFENCE'S mRNA WITH ACCUMTM FOR CANCER VACCINES UPDATE

Retrieved on: 
Sunday, December 18, 2022
Cell, Protein, Neoplasm, Vaccination, Animal, Catastrophic illness, Engineering, Cancer, ADC, Control, News, Vaccine, Cytoplasm, CSE, RNA transfection, USD, Infection, Therapy, Security (finance), Pharma, Defense

The Defence team is therefore working with a private European company to synthesize mRNA vaccines coupled with AccumTM.

Key Points: 
  • The Defence team is therefore working with a private European company to synthesize mRNA vaccines coupled with AccumTM.
  • The objective of this study is to demonstrate that AccumTM can significantly enhance the therapeutic potency of a given mRNA vaccine”, says Mr. Plouffe, CEO of Defence Therapeutics.
  • “Once completed, Defence will have in its possession its own 100% owned mRNA with AccumTM vaccine for cancer.
  • Defence will also be in a position to license its personalized AccumTM technology to any Pharma company with mRNA vaccines”, he adds.

EQS-News: Chinese Lockdown Effects Ripple Marketwide; A Solution Urgently Needed

Retrieved on: 
Sunday, December 18, 2022
Acquisition, R, Sunlight, Pancreatic cancer, NYSE, Health, Advertising, AAPL, Safety, Cancer, Regeneron Pharmaceuticals, Tesla, McGill, COVID-19, Vaccine, General Hospital, Eli Lilly and Company, RNA transfection, Squamous cell carcinoma, Breast cancer, LLY, Apple, Growth, TSLA, Immune system, Research, University, Combined small-cell lung carcinoma, Patient, Drug resistance, PFE, COVID, Pharmaceutical industry, Pfizer

Chinese Lockdown Effects Ripple Marketwide; A Solution Urgently Needed

Key Points: 
  • Chinese Lockdown Effects Ripple Marketwide; A Solution Urgently Needed
    Protests have mounted in intensity across China in the past weeks, as more and more citizens become frustrated with the country’s radical “Zero-Covid” policies.
  • Sunshine Biopharma, Inc. (NASDAQ: SBFM) is a Canada-based pharmaceutical company combating COVID-19 through the development of SBFM-PL4, an antiviral treatment.
  • The company is confident that, in a Covid-19 vaccine market worth $13.6 billion , its drug candidate could provide a welcome solution.
  • Studies using non-transformed (normal) human cells (HMEC) have shown that K1.1 mRNA had little or no cytotoxic effects.